Agios Pharmaceuticals to Present at 31st Annual Cowen Healthcare Conference
Cambridge, Mass. – March 1, 2011 – Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that Duncan Higgons, chief operating officer, is scheduled to present at the 31st Annual Cowen Healthcare Conference on Tuesday, March 8, 2011 at 3:30p.m. EST at the Boston Marriott Copley Place in Boston.
Mr. Higgons is expected to discuss the potential of cancer metabolism, one of the most promising new areas of medicine, as well as the assets and capabilities that position Agios as a leader in this field.
About Agios Pharmaceuticals
Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism. To support and drive these efforts, Agios is building a robust platform integrating cancer biology, metabolomics, biochemistry and informatics to enable target and biomarker identification. Agios’ capabilities to interrogate differential cellular metabolism of diseased cells relative to normal cells may also be applicable to other therapeutics areas including autoimmune, inflammatory and neurological diseases. To date, Agios has put in place a world-class scientific team of more than 60 people, built a fully integrated cell metabolism platform within the largest research laboratory dedicated to cancer metabolism, and created an emerging product development pipeline of novel cancer therapeutics. The company’s founders represent the core thought leaders in the field of cancer metabolism, responsible for key advances, insights and discoveries in the field. Agios Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company\'s website at www.agios.com.
